Literature DB >> 16322845

Deep stromal mycobacterial keratitis: viable bacteria after six months of treatment: case report and literature review.

Filipe Accioly de Gusmão1, Lênio Alvarenga, Luciene Barbosa, Jorge Sampaio, Sylvia Cardoso Leão, Ana Luisa Hofling-Lima, Denise de Freitas.   

Abstract

To report the presence of viable mycobacteria in a patient with keratitis treated for 6 months. Species identification was performed using the PRA method (polymerase chain reaction followed by restriction endonuclease analysis). Clonality was evaluated with RAPD (randomly amplified polymorphic DNA) and ERIC-PCR (enterobacterial repetitive intergenic consensus-polymerase chain reaction) methods. The patient reported trauma due to a metallic foreign body 3 weeks prior to presentation. Initial corneal scraping cultures revealed Mycobacterium abscessus. After 6 months of topical and systemic treatment the patient presented with no active inflammation and was considered clinically cured. An optic penetrating keratoplasty was performed. Culture of the excised cornea revealed Mycobacterium abscessus. Both isolates had the same clonal origin. The most interesting finding of this case report was the positive culture of the excised cornea after 6 months of intensive specific topical therapy. To our knowledge, this is the first report in the literature showing this possibility in the treatment of Mycobacterial keratitis. Thus, Mycobacterium abscessus may present viable bacteria after long-term treatment and should be followed carefully for a long period of time after tapering the medication.

Entities:  

Mesh:

Year:  2005        PMID: 16322845     DOI: 10.1590/s0004-27492005000400024

Source DB:  PubMed          Journal:  Arq Bras Oftalmol        ISSN: 0004-2749            Impact factor:   0.872


  1 in total

1.  Mycobacterium abscessus subsp. bolletii keratitis: rare case reported in Brazil.

Authors:  Sabrina Cavaglieri Silva; Isabela Neves de Almeida; Wesley Campos Ribeiro; Silvana Spíndola de Miranda; Anna Christina Higino Rocha
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2020-02-07       Impact factor: 1.846

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.